In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The closing price of Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) was $20.58 for the day, down -1.06% from the previous closing price of $20.80. In other words, the price has decreased by -$1.06 from its previous closing price. On the day, 1.28 million shares were traded.
Ratios:
Our analysis of CPRX’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 5.55 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 13.06. For the most recent quarter (mrq), Quick Ratio is recorded 4.92 and its Current Ratio is at 5.11. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Robert W. Baird on February 04, 2025, initiated with a Outperform rating and assigned the stock a target price of $28.
On November 18, 2024, Stephens started tracking the stock assigning a Overweight rating and target price of $35.
On March 14, 2024, Citigroup started tracking the stock assigning a Buy rating and target price of $27.Citigroup initiated its Buy rating on March 14, 2024, with a $27 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Dec 10 ’24 when Miller Steve sold 50,000 shares for $21.93 per share. The transaction valued at 1,096,350 led to the insider holds 686,996 shares of the business.
Miller Steve bought 50,000 shares of CPRX for $1,096,333 on Dec 10 ’24. On Nov 27 ’24, another insider, INGENITO GARY, who serves as the Chief Med. & Reg. Officer of the company, sold 12,000 shares for $22.72 each. As a result, the insider received 272,654 and left with 51,391 shares of the company.
Valuation Measures:
As of this moment, Catalyst’s Price-to-Earnings (P/E) ratio for their current fiscal year is 17.56, and their Forward P/E ratio for the next fiscal year is 11.67. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.35. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.33 while its Price-to-Book (P/B) ratio in mrq is 3.71.
Stock Price History:
Over the past 52 weeks, CPRX has reached a high of $24.64, while it has fallen to a 52-week low of $13.91. The 50-Day Moving Average of the stock is -7.02%, while the 200-Day Moving Average is calculated to be 4.39%.
Shares Statistics:
A total of 119.27M shares are outstanding, with a floating share count of 108.44M. Insiders hold about 9.08% of the company’s shares, while institutions hold 80.13% stake in the company.
Earnings Estimates
The stock of Catalyst Pharmaceuticals Inc (CPRX) is currently in the spotlight, with 5.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is $0.52, with high estimates of $0.62 and low estimates of $0.33.
Analysts are recommending an EPS of between $2.47 and $1.16 for the fiscal current year, implying an average EPS of $1.94. EPS for the following year is $2.03, with 3.0 analysts recommending between $2.56 and $1.07.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 8 analysts. It ranges from a high estimate of $134.34M to a low estimate of $120M. As of the current estimate, Catalyst Pharmaceuticals Inc’s year-ago sales were $98.51MFor the next quarter, 8 analysts are estimating revenue of $139.91M. There is a high estimate of $144.74M for the next quarter, whereas the lowest estimate is $131.06M.
A total of 9 analysts have provided revenue estimates for CPRX’s current fiscal year. The highest revenue estimate was $624.15M, while the lowest revenue estimate was $532.89M, resulting in an average revenue estimate of $558.08M. In the same quarter a year ago, actual revenue was $491.73MBased on 7 analysts’ estimates, the company’s revenue will be $632.27M in the next fiscal year. The high estimate is $711.1M and the low estimate is $575.75M.
